Summary of ESC-HSC phenotype transplants
| EPOCH cell population . | No. of unfractionated equivalents transplanted, × 106* . | No. of cells transplanted, × 106 . | No. of mice rescued at 4 wks after transplant/ no. transplanted . | Peripheral blood engraftment long-term† . | No. of animals displaying multilineage engraftment‡ . |
|---|---|---|---|---|---|
| CD41+§ | 3-5 | 1.9-4.4 | 6/6 | 15.5%-85% | 4 |
| CD41−§ | 3-5 | 0.6-1.1 | 0/6 | ||
| CD45+§ | 3-5 | 1.4-2 | 5/6 | 1%-41% | 2 |
| CD45−§ | 3-5 | 1.7-3 | 6/6 | 3.6%-64% | 2 |
| CD45+CD41low§ | 2-3 | 0.14-0.3 | 0/6 | ||
| CD45−CD41low§ | 2-3 | 0.12-0.11 | 0/6 | ||
| CD45+CD41high§ | 2-3 | 0.13-0.3 | 5/6 | 9.7%-63% | 1 |
| CD45−CD41high§ | 2-3 | 0.4-0.5 | 3/6 | 83%-91% | 1 |
| CD34+ | 2.5 | 0.125 | 0/3 | nd | nd |
| CD34− | 2.5 | 1.4 | 1/2 | nd | nd |
| CD41+CD34+§ | 1.5-2 | 0.023-0.3 | 0/6 | ||
| CD41+CD34−§ | 1.5-2.5 | 0.3-0.9 | 4/4 | 4.3%-91% | 3 |
| CD48−§ | 5 | 1.75-1.8 | 2/3 | 8.4%-65% | 1 |
| CD48+§ | 5 | 2.8-3.1 | 5/6 | 1.5%-90% | 3 |
| CD41highCD150+CD48-¶ | 2-5 | 0.016-0.4 | 2/7 | 7.2% | |
| CD41highCD150+CD48med¶ | 2-5 | 0.35-0.75 | 4/11 | 2.4% | 1 |
| CD41highCD150+CD48+¶ | 2-5 | 0.5-1 | 6/9 | 0.2%-14.4% | 3 |
| EPOCH cell population . | No. of unfractionated equivalents transplanted, × 106* . | No. of cells transplanted, × 106 . | No. of mice rescued at 4 wks after transplant/ no. transplanted . | Peripheral blood engraftment long-term† . | No. of animals displaying multilineage engraftment‡ . |
|---|---|---|---|---|---|
| CD41+§ | 3-5 | 1.9-4.4 | 6/6 | 15.5%-85% | 4 |
| CD41−§ | 3-5 | 0.6-1.1 | 0/6 | ||
| CD45+§ | 3-5 | 1.4-2 | 5/6 | 1%-41% | 2 |
| CD45−§ | 3-5 | 1.7-3 | 6/6 | 3.6%-64% | 2 |
| CD45+CD41low§ | 2-3 | 0.14-0.3 | 0/6 | ||
| CD45−CD41low§ | 2-3 | 0.12-0.11 | 0/6 | ||
| CD45+CD41high§ | 2-3 | 0.13-0.3 | 5/6 | 9.7%-63% | 1 |
| CD45−CD41high§ | 2-3 | 0.4-0.5 | 3/6 | 83%-91% | 1 |
| CD34+ | 2.5 | 0.125 | 0/3 | nd | nd |
| CD34− | 2.5 | 1.4 | 1/2 | nd | nd |
| CD41+CD34+§ | 1.5-2 | 0.023-0.3 | 0/6 | ||
| CD41+CD34−§ | 1.5-2.5 | 0.3-0.9 | 4/4 | 4.3%-91% | 3 |
| CD48−§ | 5 | 1.75-1.8 | 2/3 | 8.4%-65% | 1 |
| CD48+§ | 5 | 2.8-3.1 | 5/6 | 1.5%-90% | 3 |
| CD41highCD150+CD48-¶ | 2-5 | 0.016-0.4 | 2/7 | 7.2% | |
| CD41highCD150+CD48med¶ | 2-5 | 0.35-0.75 | 4/11 | 2.4% | 1 |
| CD41highCD150+CD48+¶ | 2-5 | 0.5-1 | 6/9 | 0.2%-14.4% | 3 |
nd indicates not determined.
Unfractionated equivalent numbers are calculated based on the frequency of each phenotypic subpopulation within the total EPOCH population. For example, 1 × 105 cells of a subset of cells representing 10% of the total population would be equivalent to 1 000 000 unfractionated EPOCH cells.
Peripheral blood engraftment based on the frequency of green fluorescent protein-positive cells in the peripheral blood of surviving mice undergoing transplantation at > 18 weeks after transplantation.
Multilineage engraftment is defined by the presence of cells in the PB of mice undergoing transplantation coexpressing green fluorescent protein and Mac-1 and/or Gr-1 (myeloid engraftment) and cells expressing CD19 and/or IgM (B cells) or CD3 and CD4/CD8 (T cells) > 22 weeks after transplantation.
Pooling of data from 2 independent experiments
Pooling of data from 4 independent experiments.